Agios Pharmaceuticals (AGIO) vs Stoke Therapeutics (STOK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Agios Pharmaceuticals (AGIO) has outperformed Stoke Therapeutics (STOK) over the past year, gaining 9.4% versus a loss of 8.6%. Over five years, STOK leads with a +6.8% price change compared with -24.3% for AGIO. Stoke Therapeutics is the larger company by market cap ($1.75 billion vs $1.65 billion), about 1.1 times the size.
Stoke Therapeutics converts more of its revenue into profit, with a net margin of -3.7% versus -764.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGIO | STOK |
|---|---|---|
| Share price | $27.60 | $26.81 |
| Market cap | $1.65B | $1.75B |
| 1-day change | -4.03% | -0.45% |
| YTD return | +1.40% | -15.53% |
| 1-year return | +9.35% | -8.62% |
| 5-year return | -24.28% | +6.77% |
| EPS (TTM) | $-6.31 | $-3.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $54.03M | $184.42M |
| Revenue growth (YoY) | +48.03% | +404.50% |
| Net income (latest FY) | $-412.78M | $-6.88M |
| Gross margin | 88.26% | — |
| Operating margin | -873.87% | -11.16% |
| Net margin | -764.01% | -3.73% |
| 52-week high | $44.09 | $40.22 |
| 52-week low | $24.16 | $22.05 |
| Distance from 52-week high | -37.40% | -33.34% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +67.07% | +73.00% |
| Average volume | 1.06M | 1.02M |
| Shares outstanding | 59.81M | 65.41M |
| Employees | 539 | 170 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AGIO has outperformed STOK by 18.0 percentage points over the past year.
- Stoke Therapeutics is more profitable, keeping -3.7 cents of every revenue dollar as net income versus -764.0 cents for Agios Pharmaceuticals.
- Stoke Therapeutics grew revenue faster in its latest fiscal year (+404.50% vs +48.03%).
About Agios Pharmaceuticals
AGIO stock →Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency.
Health Care · Biotechnology: Pharmaceutical Preparations · 539 employees
About Stoke Therapeutics
STOK stock →Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression.
Health Care · Biotechnology: Pharmaceutical Preparations · 170 employees
AGIO vs STOK FAQ
Which is bigger, Agios Pharmaceuticals or Stoke Therapeutics?
Stoke Therapeutics (STOK) is larger, with a market capitalization of $1.75B compared with $1.65B for Agios Pharmaceuticals (AGIO).
Which stock has performed better over the past year, AGIO or STOK?
AGIO returned +9.35% over the past 12 months, compared with -8.62% for STOK (price return, excluding dividends). Past performance does not predict future results.
Are Agios Pharmaceuticals and Stoke Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.